Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 16/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727768 | 0.92 | FSHR (0.86) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3396723 | 0.89 | FSHR (0.80) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322857 | 0.88 | FSHR (0.78) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL5728539 | 0.88 | FSHR (0.78) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL5731918 | 0.87 | FSHR (0.77) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322362 | 0.86 | FSHR (0.76) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL1323743 | 0.86 | MAPT (0.76) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL3392106 | 0.86 | FSHR (0.75) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322184 | 0.85 | FSHR (0.74) | FSHRTSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322278 | 0.85 | TSHR (0.82) | FSHRTSHRMEN1ADRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | claimed |
| EP-2197445-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. Organon (NL) | 2010-06-23 | — | — | EP | claimed |
| WO-2009027482-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. ORGANON (NL) | 2009-03-05 | — | — | WO | claimed |
| EP-1406628-B1 | TETRAHYDROQUINOLINE DERIVATIVES | AKZO NOBEL NV (NL) | 2006-03-08 | — | — | EP | claimed |
| EP-2197445-B1 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2017-04-19 | — | — | EP | disclosed |
| EP-2197445-B1 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2017-04-19 | — | — | EP | disclosed |
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | disclosed |
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | disclosed |
| US-8258293-B2 | Tetrahydroquinoline derivatives | MSD OSS B.V. (NL) | 2012-09-04 | — | — | US | disclosed |
| US-20120202996-A1 | TETRAHYDROQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2012-08-09 | — | — | US | disclosed |
| US-8058441-B2 | For control fertility, contraception, breast cancer, prostate cancer and endometriosis; modulating activity of the follicle stimulating hormone (FSH) receptor; 1-Acetyl-6-(tert-butoxycarbonyl)amino-4-phenyl-1,2,3,4-tetrahydro-2,2,4-trimethylquinoline | N.V. ORGANON (NL) | 2011-11-15 | — | — | US | disclosed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | disclosed |
| WO-2009027482-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. ORGANON (NL) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027482-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. ORGANON (NL) | 2009-03-05 | — | — | WO | disclosed |
| EP-1578726-B1 | TETRAHYDROQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-02-25 | — | — | EP | disclosed |
| US-20060142334-A1 | Tetrahydroquinoline derivatives | MERCK SHARP & DOHME B.V. (NL) | 2006-06-29 | — | — | US | disclosed |
| EP-1406628-B1 | TETRAHYDROQUINOLINE DERIVATIVES | AKZO NOBEL NV (NL) | 2006-03-08 | — | — | EP | disclosed |
| US-20040236109-A1 | Tetrahydroquinoline derivatives | MERCK SHARP & DOHME B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| EP-1406628-A1 | TETRAHYDROQUINOLINE DERIVATIVES | Akzo Nobel N.V. (NL) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004028-A1 | TETRAHYDROQUINOLINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142334-A1 | Tetrahydroquinoline derivatives | GNRHR, KCNH3, HCAR3 | FSHR 9/4885TSHR 628/4885MEN1 2286/4885 |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | TSHR, MC1R, TRHR | FSHR 21/4885TSHR 1/4885MEN1 74/4885 |
| US-20120202996-A1 | TETRAHYDROQUINOLINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ODC1, COX6C | FSHR 1154/4885TSHR 412/4885MEN1 2716/4885 |
| US-20040236109-A1 | Tetrahydroquinoline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AOC2, HTR3C | FSHR 1485/4885TSHR 725/4885MEN1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.